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ABSTRACT
Ubiquitin has previously been identified as another natural agonist of CXC
chemokine receptor 4 (CXCR4). In addition, recent evidence suggests that ubiquitin may
activate CXCR4 through a binding site on the receptor, which is distinct from the binding site
for the cognate ligand stromal cell-derived factor (SDF)-1!. The cellular consequences of
ubiquitin induced CXCR4 activation, however, are still poorly defined and a side-by-side
comparison of CXCR4 mediated functions after activation with SDF-1! and ubiquitin is
lacking. Such information will be instrumental to better understand the physiological
function of CXCR4 and to further define its role as a therapeutic target in various disease
processes. Accordingly, the aim of this study was to determine and compare CXCR4
mediated effects on important signal transduction pathways and chemotaxis, a key function
of CXCR4, upon receptor activation with ubiquitin and SDF-1!. Utilizing a MAPK array in
combination with Western blot experiments, it is shown that activation of CXCR4 with
ubiquitin and SDF-1! in THP-1 cells leads to increased phosphorylation of extracellular
signal-related kinase (ERK) 1/2, ribosomal S6 kinase (RSK) 1, and protein kinase B (Akt).
Analyses of the time progression of the MAPK phosphorylation revealed that both ligands
induced a comparable degree of MAPK phosphorylation, which occurred transiently after
activation of CXCR4 with ubiquitin and was sustained for at least 30 minutes with SDF-1!.
To assess CXCR4 mediated chemotaxis, a filter migration assay was established and
optimized. It is shown that THP-1 cells and human peripheral blood mononuclear cells
viii

migrate dose dependently towards ubiquitin and SDF-1!. Under optimized conditions,
ubiquitin was 4-5 times less efficacious than SDF-1! in promoting chemotaxis, but of similar
potency. Pharmacological inhibition of signal transduction molecules that are known to be
involved in the regulation of CXCR4 mediated chemotaxis resulted in similar effects on
ubiquitin and SDF-1! induced chemotaxis in THP1 cells and PBMCs. This suggests that
both ligands rely on a similar pattern of intracellular signaling to induce chemotaxis. In
conclusion, activation of CXCR4 with ubiquitin and SDF-1! results in similar intracellular
signaling events and functional consequences. With activation of CXCR4 by ubiquitin,
however, serine/threonine protein kinase phosphorylations occurred more transiently, which
could account for its weaker chemotactic activity, as compared with SDF-1!. Thus, ubiquitin
appears to be a weaker CXCR4 agonist than SDF-1!, which may correspond to differential
CXCR4 signaling mediated via distinct ligand binding sites on the receptor.
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CHAPTER ONE
INTRODUCTION
G-protein coupled receptors
G-protein coupled receptors (GPCRs) are a large superfamily of transmembrane
spanning receptor proteins found in the human genome and are present in all eukaryotes (13). The superfamily is further divided into three main sub-families: the most prominent being
rhodopsin related (type A), receptors related to secretin/calcitonin (type B) and receptors
related to the metabotropic receptors (type C) (4). All GPCRs have an extracellular Nterminal segment, a seven transmembrane spanning region, which form the transmembrane
core, three extra cellular loops, three cytoplasmic loops, and an intracellular C-terminal
segment. Ligand binding to the extracellular region causes a receptor conformational change
(5,6) and GPCRs fluctuate between an active and inactive conformation (11). In the active
state, they utilize several molecular mechanisms to induce a cellular response through two
distinct signaling pathways (Figure 1-1): G-protein mediated signaling, the predominant
signaling pathway, and G-protein independent signaling (7-9).
In the G-protein mediated signaling pathway, a heterotrimeric G-protein complex
comprised of !"# subunits are in an inactive state at the receptor and the localization is a
result of the G! subunit being bound to GDP (46-48). The binding of an agonist induces an
activating conformational receptor shift (49, 50). This shift enables GPCRs to act as a
guanine nucleotide exchange factor, promoting the heterotrimeric G-protein activation
resulting in GDP to GTP exchange at the G! subunit (49,50) Subsequently, there is a
conformational change in the heterotrimeric G-protein complex resulting in G! and G"#
1
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disassociation and activation of various second messengers leading to a functional cellular
response (49, 50).
The G-protein independent signaling pathway is well established through "-arrestin
mediated signaling (8, 45, 60-63). This pathway requires receptor phosphorylation,
classically by G-protein-coupled receptor kinases (GRKs), but also by cAMP dependent
kinase A (PKA) or PKC on the third intracellular loop of the GPCR enabling "-arrestin to
target the receptor (8, 60). Upon receptor phosphorylation, arrestin-2 and/or arrestin-3 are
then able to bind; preventing further G-protein mediated signaling (8,45,60-63). This
pathway plays a role in regulating G! interactions and is predominantly responsible for
receptor desensitization, internalization, and degradation (29).

Figure 1-1: GPCRs can signal through two distinct signaling pathways: 1. G-protein
(left), GPCR signals through G-protein activation. 2. "-arrestin (right), GPCR signals
through "-arrestin.
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Functional selectivity (biased agonism), a phenomenon that occurs when a ligand
preferentially stabilizes an active conformation promoting only a subset of signaling effects
(11-16), has gained particular attention with respect to GPCR mediated signaling. GPCRs are
capable of adopting different active conformational states and this could lead to preferential
(biased) G-protein dependent or independent signaling (10). While most GPCR-mediated
biased signaling has been observed using synthetic agonists (14), C-C motif chemokine 19
and 21 (CCL19/21), natural agonists for GPCR C-C chemokine receptor 7 (CCR7), have
been shown to produce G-protein signaling with equal potency. CCL19 alone causes receptor
agonist-dependent phosphorylation and "-arrestin recruitment to terminate G-protein
signaling (14). There is therapeutic promise to understanding GPCR mediated biased
signaling because it broadens the scope of drug discovery tailored to receptor ligand
specificity.

Chemokine receptors
Chemokine receptors are a member of the rhodopsin related (type A, subfamily A1
and A2) GPCR superfamily and are involved in immune system functions (17-19). The
interaction of chemokine receptors with chemokines regulates cell migration for multiple cell
types including leukocytes (100, 101). The receptors are classified on the basis of the ligand
specificity for a particular chemokine class. The four main classes of chemokines are CC,
CXC, CX3C and C, according to the number and spacing of conserved cysteines in the
amino acid sequence (20, 21). Structure-function studies have shown that the chemokinereceptor interaction follows a 2-site binding model (Figure 1-2). In this model, the
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extracellular N-terminal domain of the chemokine receptor (site I) initially interacts with a
ligand for binding. The ligand then interacts with the chemokine receptor at a different
receptor extracellular site (site II) to induce an activation signal (24, 43). It is known that
there are 19 human chemokine receptors and over 50 distinct chemokines. As a result,
chemokine receptors, like CCR7, are promiscuous in that they can bind more than one
chemokine (14, 22, 23).

Figure 1-2:Two site binding model of the chemokine – receptor interaction. Depicted is a
model of the chemokine-chemokine receptor interaction. Chemokines binds to a site on the
N-terminal domain of a chemokine receptor and then to a different site on the chemokine
receptor to induce activation.
CXC chemokine receptor 4 (CXCR4)
CXC chemokine receptor 4 (CXCR4) was initially discovered as an orphan receptor
leukocyte-derived seven-transmembrane domain protein (LESTR) (84) and is encoded by the
CXCR4 gene (25, 26). Recently, small protein antagonists were used to determine the crystal
structure of CXCR4 and it provided additional evidence CXCR4 is capable of existing as a
homo- and hetero-dimer on the cell surface (102). The currently known endogenous CXCR4
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ligands are stromal-cell derived factor 1 (SDF-1!), macrophage migration inhibitory factor
(MIF) and ubiquitin (28-32). Site-directed mutagenesis experiments suggest CXCR4 may
have 2 separate ligand binding sites for ubiquitin and SDF-1! (44).

CXCR4 ligands
Stromal-cell derived factor-1 alpha (SDF-1!)
Human stromal cell-derived factor 1 alpha (SDF-1!), commonly referred to as
chemokine (C-X-C motif) ligand (CXCL12), is a small (8 kDa) protein that is ubiquitously
expressed in many tissues such as the liver, pancreas, and spleen (105). The CXCL12 gene
encodes different isoforms of SDF-1, SDF-1! and SDF-1", and the two spice variants arise
as a result of alternative splicing (103). SDF-1! exists as a monomer but can homo-dimerize
under non-acidic pH conditions in the presence of stabilizing counterions and then displays
partial agonist activity (104). While it has been well described that SDF-1! is the cognate
ligand for CXCR4 and binds with high affinity (Kd: 1.5 – 24 nM) (106, 107), SDF-1! is
promiscuous in that it has also been described as a CXCR7 agonist (33). Mutagenesis
experiments to synthesize SDF-1! analogs and subsequent calcium flux and binding assays
suggest SDF-1! utilizes the classical two-site binding mechanism of chemokine-receptor
interactions (33-35, 36-39). The docking domain of SDF-1! interacts with the N-terminus of
CXCR4 to bind to the receptor (site I) and the flexible N-terminus of SDF-1! interacts with
the central binding pocket of CXCR4 (site II) to activate the receptor (40) (Figure 1-3).
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Figure 1-3: Structural requirements of SDF-1! for CXCR4 binding and activation:
Depicted is a ribbon diagram of the structure of SDF-1!. The blue box in the middle of the
image depicts the RFFESH residues on SDF-1! that interact with CXCR4 for docking. The
blue box to the left depicts the K1 and P2 residues on SDF-1! that interact with CXCR4 for
receptor activation.
Ubiquitin
Ubiquitin is a small (8.5 kDa), heat stable protein present in every eukaryotic cell (41)
encoded by 4 mammalian genes. Recent mutagenesis experiments suggest UBA52 and
RPS27A genes code for mono ubiquitin and UBB and UBC genes code for polyubiquitin
precursor proteins (108). Ubiquitin is highly conserved and is most known for its intracellular
functions in the ubiquitin-proteasome pathway of protein degradation (42). Ubiquitin is also
present outside the cell and kinetic binding experiments suggest ubiquitin, like SDF-1!,
binds to CXCR4 with a Kd of ~100 nM (28). Ubiquitin is distinct from SDF-1!, however,
because it does not share CXCR7 as a receptor (43). Nuclear magnetic resonance (NMR)
spectroscopy with the N-terminal domain of CXCR4, receptor binding and signaling studies
in presence of antibodies directed against specific regions of CXCR4 suggesting ubiquitin,
unlike SDF-1!, does not interact with the CXCR4 N-terminus for receptor docking (43).
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Subsequent site-directed mutagenesis of CXCR4 followed by receptor binding experiments
suggest there are distinct sites on the receptor important for ubiquitin-CXCR4 binding, but
not for SDF-1! (43) (Figure 1-4).

Figure 1-4: Molecular basis of the CXCR4 agonist activity of ubiquitin. Depicted is a
ubiquitin-CXCR4 interaction model. Ubiquitin does not follow the typical two-site binding
model of chemokine receptor interactions because the receptor N-terminus is not required for
ubiquitin binding to CXCR4.
Furthermore, experiments with ubiquitin point mutants suggest that the binding of ubiquitin
to CXCR4 follows the two-site model of the structure function relationship of chemokines
(44) (Figure 1-5).

Figure 1-5: Structural requirements of ubiquitin for CXCR4 binding and activation:
Depicted is a ribbon diagram of the structure of ubiquitin. The 2 blue boxes correspond to the
blue arrows and show residues F4 and V70 interact with CXCR4 and are responsible for
receptor docking. The red arrow corresponds to the red box on the model and shows G75 and
G76 interact with CXCR4 for receptor activation.
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Macrophage Migration Inhibitory factor (MIF)
Macrophage migration inhibitory factor is a lymphokine that is encoded by the MIF
gene and is a trimer comprised of three identical subunits (109, 110). It has been suggested
MIF is a regulator of innate immunity by promoting pro-inflammatory functions of immune
cells, specifically macrophage migration (111). While it has been described MIF is a ligand
for CXCR4, MIF is promiscuous in that it has also been shown to bind CD74 and CXCR2
(112). Information on the structure function relationship of the MIF-CXCR4 interaction is
currently not available.

CXCR4 signaling
CXCR4 signals through G-protein dependent and independent signaling upon ligand
binding and signaling is regulated by three processes: receptor desensitization, receptor
internalization, and receptor degradation (115). CXCR4 is a G!i coupled receptor and
pertussis toxin, a potent G!i protein inhibitor, has been pivotal in elucidating the distinct
signaling pathways (115). Through G-protein dependent signaling, it has been described
CXCR4 can inhibit adenylyl cyclase, the enzyme that synthesizes cyclic adenosine
monophosphate (cAMP) (115). Other resulting intracellular signals of G-protein mediated
signaling are calcium fluxes and activation of focal adhesion components, protein kinase C
(PKC), phospholipase C (PLC) as well as mitogen-activated protein kinases (MAPK p42/44)
and phosphoinositide 3-kinase (PI3-K)/Protein Kinase B (PKB/Akt) activation (29, 50-52,
53-59).
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As previously described, G-protein independent signaling is thought to be mainly responsible
for receptor desensitization. There is evidence, however, that the "-arrestin pathway also
results in other signal transduction cascades, leading to cellular responses such as
serine/threonine specific protein kinase activation (45, 61-63).
Serine/Threonine specific protein kinases are cell-signaling enzymes that
phosphorylate the hydroxyl group of serine and threonine protein residues (64). These
kinases can respond to extracellular stimuli and ultimately regulate a variety of cellular
functions (64). There are many sub-classifications of these kinase types including mitogenactivated protein kinase (MAPK) and protein kinase B (Akt).
Mitogen-activated protein kinases (MAPKs) are signaling molecules involved in
migration and survival. Activation of CXCR4 leads to G-protein mediated phosphorylation
of the MAPK extracellular signal-related kinase (ERK) 1/2 (65-67) and subsequently ERK
1/2 phosphorylates ribosomal S6 kinase (RSK) 1 (68) (Figure 1-6). It has also been described
cell migration can be regulated by CXCR4 induced ERK1/2 activation (69,70).
Protein kinase B (Akt) is a signaling molecule that is also involved in cell survival
and migration (71,72). Akt has been implicated to be activated through CXCR4 mediated Gprotein signaling (66) (Figure 1-6). Akt also can regulate CXCR4 mediated cell migration
(69,72).
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Figure 1-6: G-protein coupled receptor mediated serine/threonine protein kinase
activation: Left: G proteins function as guanine nucleotide exchange factors and act on Ras.
Ras then binds Raf and initiates a phosphorylation cascade, acting on mitogen-activated
protein kinase kinase MEK-1/2 and then activating ERK-1/2. Right: G proteins fucntion as
guanine nucleotide exchange factors and act on PI3-K. PI3-K then phosphorylates the 3-OH
position of phosphatidylinositol (4,5)-bisphosphate (PIP2) resulting in phosphatidylinositol
(3,4,5)-trisphosphate PIP3. PIP3 then acts as a lipid anchor for phosphoinositide-dependent
kinase-1 (PDK1) and Akt. Akt is then phosphorylated by PDK1 and PDK2.
Function of CXC chemokine receptor 4
CXCR4 is abundant in leukocytes and in most human tissues and plays pleiotropic
roles as an immune modulator (27). CXCR4 is involved in platelet aggregation and reduces
the production of tumor necrosis factor-! (TNF-!) and enhances interleukin (IL) 10
production under inflammatory conditions (93-95). CXCR4 is crucial for normal
development and CXCL12 (SDF-1!) and CXCR4 gene knockouts in mice models are
embryonic lethal because the mice display defective vasculogenesis, neurogenesis,
hematopoeisis, and cardiogenesis (73-77, 89, 90). It has also been described ubiquitin gene
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knockouts are embryonic lethal but it is unknown if this is due to lack of ubiquitin-CXCR4
binding (108). There are many disease states associated with CXCR4 dysregulation:
When CXCR4 is in an unbound state, the receptor acts as a co receptor for human
immunodeficiency virus (HIV-1) and has been described as a drug target for HIV-1 infection
(78,79). The interaction between SDF-1! and CXCR4 has been shown to interfere with
productive cellular entry of HIV-1 (34,35,80). This phenomenon does not occur when
ubiquitin interacts with CXCR4 (43).
CXCR4 is highly expressed on 23 different cancer cell types (115) including prostate,
gastric, lung, and breast (85-88). CXCR4 has previously been implicated as a drug target for
cancer (73,78) given that the regulation of chemotaxis is regarded as a key function of the
CXCR4 signaling axis. Chemotaxis is the directed movement of cells toward a chemical
gradient that is dependent on cell type and environmental conditions (81). As a result,
CXCR4 expression may correlate with metastases, which is the spread of cancer from one
part of the body to another (115). Gene expression profiles and in vivo studies suggest there
are multiple cancer cell types that metastasize to areas that express high levels of SDF-1!
(116,117). While variation exists between cancer cell types, CXCR4 mediated chemotaxis is
regulated by a set of intracellular signal transduction pathways including G!i, PLC,
PI3K/Akt and MAPK Erk1/2 activation (69,70,72,82,83).
Warts, hypogammaglobulinemia, infection, and myelokathexis (WHIM) syndrome is
a dominant inherited primary immunodeficiency disorder of the CXCR4 gene (96). Further
genetic evidence suggests a single amino acid substitution in the carboxy-terminus of
CXCR4 can lead to truncation of the C-terminal tail and elimination of possible
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phosphorylation sites. The C-terminal tail truncation may lead to a hyperactive receptor,
because GRKs can not phosohorylate the receptor and induce desensitization. This ultimately
results in an increased responsiveness to SDF-1! (97,99). The lack of receptor
desensitization (113) results in enhanced cellular chemotaxis (113), enhanced calcium flux
(114), and a decrease in SDF-1! promoted internalization (113,114). The name of the
disease describes the significant clinical symptoms (98).

Rationale of study
Biased agonists result in biased intracellular signaling and different biological functions
through the same receptor, but the mechanisms leading to these effects are largely unknown.
It is known that ubiquitin and SDF-1! bind to CXCR4 at distinct ligand binding sites (43).
They do not, however, share CXCR7 as a receptor and ubiquitin also does not interfere with
HIV-1 entry (43). We therefore propose that distinct ligand binding sites for ubiquitin and
SDF-1! on CXCR4 are a structural correlate for biased agonism and result in different
biological responses. The cellular consequences of ubiquitin induced CXCR4 activation,
however, are still poorly defined and a side-by-side comparison of CXCR4 mediated
functions after activation with SDF-1! and ubiquitin is lacking. This information will be
instrumental to better understand the physiological roles of CXCR4 and to further define its
role as a therapeutic target in various disease processes.

CHAPTER TWO
HYPOTHESIS AND SPECIFIC AIMS
Hypothesis
Based on the foregoing literature review, we proposed the hypothesis that distinct
ligand binding sites for ubiquitin and SDF-1! on CXCR4 are a structural correlate for
biased agonism and result in differential biological responses upon activation of
CXCR4 with ubiquitin and SDF-1!.
To address this hypothesis, we developed the following specific aims:
Aim 1. To assess and compare the activation of important intracellular signal
transduction pathways upon CXCR4 activation with SDF-1! and ubiquitin.
Aim 1A. To screen the phosphorylation status of multiple MAPKs after CXCR4
activation with ubiquitin and SDF-1! utilizing a human phospho-MAPK array
Aim 1B. To confirm positive signals from the MAPK array by Western blotting
Aim 1 C. To define and compare the time course of phosphorylation of the
identified MAPKs after CXCR4 activation with SDF-1! and ubiquitin
Aim 2. To determine and compare the effects of ubiquitin and SDF-1! on chemotaxis
Aim 2A. To establish and optimize a chemotaxis assay
Aim 2B. To determine and compare chemotactic effects of ubiquitin and SDF-1!
Aim 2C. To evaluate the signaling events leading to chemotaxis induced by
ubiquitin and SDF-1!.
13

CHAPTER THREE
MATERIALS AND METHODS
Materials:
Ubiquitin: Ubiquitin was purchased from Boston Biochem (Cat # U-100) and
suspended in 10 mM phosphate-buffered saline solution (PBS, containing 138 mM NaCl, 2.7
mM KCl, 2 mM KH2PO4, and 10 mM Na2HPO4, pH 7.4, Sigma-Aldrich (Cat # P3813)). The
working concentration varied by experiment.
N-Terminal Biotin labeled ubiquitin: N-terminal biotin labeled ubiquitin was
purchased from Boston Biochem (Cat # UB-560) and suspended in PBS.
SDF-1!: SDF-1! was purchased from Peprotech (Cat # 300-28A) and was
suspended in PBS. The working concentration varied by experiment.
Fetal Bovine Serum (FBS): FBS was purchased from Sigma-Aldrich (Cat # F6765).
Bovine Serum Albumin (BSA): BSA was purchased from Sigma-Aldrich (Cat #
9048-46-8).
Histopaque density gradient cell separation media (Histopaque): Histopaque was
purchased from Sigma-Aldrich (Cat # 10771).
Trypan blue: Trypan blue was purchased from Lonza (Cat # 17-942E)
ELISA plate strips: ELISA plate strips were purchased from Greiner Bio-One (Cat #

762061).
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3,3’,5’5, Tetramethylbenzidine (TMB): TMB was purchased from Sigma-Aldrich
(Cat # T0440).
Super Signal West Dura Extended Duration Substrate (Substrate detection
solution): Substrate detection solution was purchased from Thermo Scientific (Cat # 34075).
Radioimmunoprecipitation assay (RIPA) Lysis and Extraction Buffer (RIPA
buffer): RIPA buffer was purchased from Thermo Scientific (Cat # 89900).
Sodium orthovanadate (Vanadate): Vanadate was purchased from New England
BioLabs (Cat # P0758L) and suspended in double distilled water (ddH20) to a stock
concentration of 100 mM. The working concentration used was 1 mM.
Phenylmethylsulfonyl Fluoride (PMSF): PMSF was purchased from Santa Cruz
Biotechnologies (Cat # SC-3597) and suspended in methanol to a stock concentration of 10
mM. The working concentration used was 500 µM.
Precision Plus Protein Dual Color standard (Protein standard): Protein standards
were purchased from Bio Rad (Cat # 161-0374).
Laemmli sample buffer: Laemmli sample buffer was purchased from Bio Rad (Cat #
161-0737).
Polyvinylidene fluoride (PVDF) Membranes (PVDF membranes): PVDF
membranes were purchased from Bio Rad (Cat # 162-0174).
Accustain Wright-Giemsa stain: Wright-Giemsa stain was purchased from SigmaAldrich (Cat # WG128).
Pertussis Toxin (catalyzes the ADP-ribosylation of ! subunit of heterotrimeric
guanine nucleotide regulatory proteins; G! i proteins remain in GDP-bound “inactive”
state): Pertussis Toxin (from Bordetella Pertussis) was purchased from Sigma-Aldrich (Cat
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# P7208) and suspended in 500 µL ddH20 to a stock concentration of 0.1 mg/ml. The
working concentration used for cell treatments was 100 ng/mL and the incubation time was 2
hours, followed by a wash with PBS before experimentation.
U73312 (Inhibits the coupling of G protein-PLC activation, remaining
unaffected by production of cAMP): U73312 was purchased from Sigma-Aldrich (Cat #
U6756) and was suspended in dimethyl sulfoxide (DMSO) from Sigma-Aldrich, (Cat # 6768-5) to a stock concentration of 10 mM. The working concentration used for cell treatments
was 5 µM, 0.1% DMSO and the incubation time was 30 minutes, followed by a wash with
PBS before experimentation.
U73343 (Inactive analog of U73312; used as a negative control): U73343 was
purchased from Sigma-Aldrich, (Cat # U6881) and was suspended in DMSO to a stock
concentration of 10 mM. The working concentration used for cell treatment was 5 µM, 0.1%
DMSO and the incubation time was 30 minutes, followed by a wash with PBS before
experimentation.
U0126 (Selectively binds to and inhibits MEK 1/2 activity thereby preventing
ERK 1/2 phoshorylation and kinase activity): U0126 was purchased from Cell Signaling
(Cat # 9903) and suspended in DMSO to a stock concentration of 10 mM. The working
concentration used for the cell treatment was 10 !M, 0.1% DMSO and the incubation time
was 30 minutes, followed by a wash with PBS before experimentation.
LY294002 (Selectively binds to and inhibits PI3 Kinase thereby preventing Akt
phosphorylation and kinase activity): LY294002 was purchased from Cell Signaling (Cat
# 9901S) and was suspended in DMSO to a stock concentration of 10 mM. The working
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concentration used for cell treatments was 50 µM, 0.1% DMSO and the incubation time was
1 hour, followed by a wash with PBS before experimentation.
AMD3100 (Highly selective CXCR4 antagonist): AMD3100 was purchased from
Sigma-Aldrich (Cat # A5602) and suspended in PBS to a stock concentration of 50 mM. The
working concentration used for all cell treatments was 10 µM, followed by a wash with PBS
before experimentation.
Trichostatin A [(TSA), Histone deacetylase inhibitor): TSA was purchased from
Selleck Chem (Cat # S1045) and suspended in DMSO to a stock concentration of 1 mM. The
working concentration used for cell treatments was 20 µM, 0.1% DMSO and the incubation
time was 18 hours, followed by a wash with PBS before experimentation.

Antibodies:
The primary antibodies used for Western blots were anti-phospho p90 ribosomal S6
kinase (RSK1) (Ser-380) rabbit IgG, anti-phospho-ERK1 (Thr-202/Tyr-204)/ERK2 (Thr185/Tyr-187) rabbit-IgG and anti-phospho-Akt pan (Ser-473) rabbit IgG (all from R&D
Systems), each diluted 1:2000 in PBS-1% Casein blocker solution (BioRad). The secondary
antibody used was anti-rabbit IgG horseradish peroxidase (HRP)-linked whole antibody
(Amersham Biosciences) and was diluted 1:5000 in PBS-1% Casein blocker solution.
To control for protein loading, 1:1000 anti- Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mouse (Applied Biosystems) was used. The secondary antibody
used was anti-mouse IgG HRP-linked whole antibody (Amersham Biosciences) diluted
1:5000 in PBS-1% Casein blocker solution.
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The antibodies used for the competitive ubiquitin enzyme-linked immunosorbent
assay (ELISA) were anti-ubiquitin and anti-biotin peroxidase conjugate both purchased from
Sigma-Aldrich (Cat # U5379 and Cat # A4541, respectively) diluted 1:500 and 1:1000 in
PBS-1% Casein blocker solution, respectively.
Cells:
THP-1: THP-1 cells are a human acute monocytic leukemia cell line obtained from
American Type culture collection depository (ATCC) (Cat # TIB-202). Cells were cultured
in Roswell Park Memorial Institute medium from Sigma-Aldrich (RPMI 1640), (Cat #
R0883) supplemented with 10% FBS and 2% Penicillin and Streptomycin from SigmaAldrich (Cat # P4333). Cells were grown in a 37°C sterile, 95% humidified incubator
supplemented with 5% CO2. Cell were split into two parts and incubated in fresh media every
2-3 days.
Peripheral blood mononuclear cell (PBMC): PBMCs, from human peripheral
venous blood, that were drawn from healthy human donors of both sexes were isolated
according to an IRB approved protocol (118).

Experimental Methods:
PBMC isolation: Histopaque solution was allowed to equilibrate to room
temperature. Three milliliters of the histopaque solution were pipetted into 15-ml centrifuge
tubes. Then, 3 mL of freshly drawn blood were pipetted into each centrifuge tube with 3 mL
histopaque, ensuring the blood rested on the top of the histopaque solution. The centrifuge
tubes were then centrifuged at 1400 revolutions per minute (RPM) for 30 minutes. After
centrifugation, the top layer of serum was aspirated as not to disturb the middle white layer
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of PBMCs. The PBMCs were then aspirated and placed into separate centrifuge tubes and
washed with 10 mL of PBS. The tubes were then spun at 1100 RPM for 10 minutes. After
centrifugation, the PBS solution was aspirated as not to disrupt the cell pellet. The cells were
then washed again with 5 mL PBS and combined into a larger 50 mL conical tube. The 50
mL conical tube was spun at 1100 RPM for 10 minutes. The PBS was aspirated and the
PBMCs were suspended in 1 mL PBS; cells were then counted on a hematocytometer and
diluted as required.
Trypan Blue Cell Viability assay: The trypan blue viability assay was performed
according to manufacturer recommendations (Lonza). The culture samples were prepared at a
ratio of 1 part 0.4% trypan blue stain: 1 part culture sample; samples were then incubated at
room temperature for 15 minutes. The cells were then counted under a microscope at 10x
magnification on a hematocytometer. Non-viable cells stained blue and viable cells remained
unstained. The percentage of viable cells is approximated by dividing the total number of
viable cells by the total number of cells and then by multiplying by 100.
Indirect Competitive Ubiquitin ELISA: The indirect competitive ubiquitin ELISA
was performed as previously described (119). High Binding ELISA plate strips were coated
with anti-ubiquitin and incubated for 18 hours at 4°C. The plates were washed three times
with 200 µL PBS per well and were incubated with blocking buffer (1% BSA-PBS) for 1
hour. After washing three times, 60 µL of 2 µg/mL ubiquitin standard solution or 60 µL of
samples were mixed with 60 µL of 0.2 ng/mL biotinylated ubiquitin and placed in the plates.
Each sample was tested in eight dilutions. Dilutions for the standard curve and test samples
were prepared in blocking buffer. After incubation for 2 hours, the plates were washed with
200 µL PBS, 0.01% Tween-20 (PBST) per well. Then, 100 µL of anti-biotin peroxidase
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conjugate was added to each well. After one-hour incubation, the plates were washed again
with PBST and 100 µL of TMB was added to each well. The reaction was stopped after 15
minutes with 100 µL of 2N hydrochloric acid (HCl) added to each well. Optical densities
were measured using a micro plate Biotek Synergy2 plate reader (test filter, 450 nm;
reference filter, 540 nm). The ubiquitin concentration in the test sample was calculated with
the Gen5 software for Windows program, Version 1.05.11 (Bio-Tek Instruments, Inc.), from
a four-parameter logistic fit using ubiquitin as the standard (0-2000 ng/mL). The correlation
coefficients for each standard curve were 0.998-1.
Protein Kinase Phosphorylation Array: Screening of the phosphorylation status of
various protein kinases after ubiquitin and SDF-1! stimulation was performed in THP-1 cells
according to manufacturer’s instructions using a human phospho mitogen activated protein
kinase (MAPK) antibody array from R&D Systems. 107 THP-1 cells were stimulated with 1
µM of ubiquitin or SDF-1! for 10 minutes at 37ºC. Unstimulated cells served as controls in
parallel experiments. Cells were lysed in 1 mL of lysis buffer on ice for 30 minutes,
centrifuged (1,400 x g for 5 minutes) and the supernatant (=lysate) collected. 250 uL of the
cell lysate was incubated with a pre-wet array membrane for 15 hours at 4ºC. After three
washing steps at room temperature, array membranes were incubated with the diluted
antibody cocktail for 2 hours at room temperature, washed and incubated with strepavidinHRP solution for 30 minutes at room temperature. After washing of the array membranes,
substrate detection solution (prepared at a ratio of 1 luminol/enhancer solution: 1 stable
peroxide buffer) was added for 5 minutes. Images of array membranes were then captured
with a Chemi-doc XRS Imager [Quantity One V4.5.2 software (Bio-Rad)] for appropriate
exposure times.
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Preparation of cell lysates: Cells were washed with ice-cold PBS and centrifuged at
1400 RPM for 5 minutes. After centrifugation, the supernatant was aspirated and the cell
pellet remained on ice. Cells were lysed in RIPA buffer supplemented with 1 mM vanadate
and 500 !M PMSF. Lysates were vortexted immediately for 10 seconds and then placed on
ice. Samples were then sonicated with a sonic demembrator, model 100 from FisherScientific, 2 times for 20-second intervals on ice. Samples remained on ice for 15 minutes
and were then centrifuged for an additional 15 minutes, at 14000 RPM, 4ºC. The sample
supernatant was then collected and placed in a clean centrifuge tube.
Protein Quantification: Protein concentration was determined using a modified
Bradford Bio-Rad DC Protein Assay Kit II (Cat # 500-0112). A BSA standard curve was
generated with concentrations ranging from 0 mg/ml to 1.42 mg/ml. 5 uL of each standard
was pippetted in duplicate into a 12-well clear flat bottom ELISA strip. 5 ul of each cell
extract was pippetted in duplicate into a 12-well clear flat bottom ELISA strip. Then, 25 µL
of reagent A, an alkaline copper tartrate solution, and then 200 µL of reagent B, a dilute
Folin Reagent, were added to each well containing a standard or sample. The plate was then
incubated on a shaker for 15 minutes at room temperature. The micro plate was then placed
into a micro plate Biotek Synergy2 plate reader and the absorbance was read at 750 nm. The
BSA protein standard absorbance was then plotted against the BSA protein standard
concentration and a standard curve was generated by linear regression analysis. Protein
concentration of an unknown sample was then calculated from the standard linear regression
curve.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE): SDSPAGE was carried out using the Mini-Format Vertical Electrophoresis system from Bio-Rad,
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and mini-protean TGX precast gels (8.6 cm x 6.7 cm, 0.1cm thickness) of 4-20%
polacrylamide. Then, 2-10 µg/mL of the protein samples were suspended in Laemmli sample
buffer and then loaded into each lane of the mini-cast gel. A protein standard was loaded in a
lane of the mini-cast gel for all SDS-PAGE experiments. The polyacrylamide gels were run
at 150V in 1X Tris/Glycine/SDS running buffer from BioRad for 45 minutes or until bands
reached the bottom of the gel.
Western Blot: PVDF membranes were presoaked for 5 seconds in 100% MeOH, and
were then washed and equilibrated in transfer buffer (Milli-Q water (Millipore-Q Water
Purification System, Millipore), 25 mM Tris/HCl, 192 mM glycine, 20% MeOH, pH 7.4).
Extra thick mini blot size papers from BioRad were simultaneously equilibrated in transfer
buffer. A transfer “sandwich” was then assembled according to standard protocol: Blot size
paper, PVDF membrane, gel, blot size paper. The semi-dry transfer with transfer buffer was
run at 25V for 48 minutes at room temperature. The PVDF membranes were then briefly
rinsed in milli-Q water, then PBST. The membranes were then blocked in PBS-1% Casein
blocker solution for 60 minutes. After blocking, the membranes were incubated with the
respective primary antibodies in PBS-1% Casein blocker solution overnight at 4ºC. The
membranes were washed 6 times in PBST for 6 minutes and incubated with horseradish
peroxidase (HRP)-linked secondary antibody diluted 1:5000 in PBS-1% Casein blocker
solution for 1 hour at room temperature. The membranes were washed again, 6 times in
PBST for 6 minutes per wash. After the final wash, the membranes were incubated with the
substrate detection solution (prepared 1 part luminol/enhancer solution to 1 part stable
peroxide buffer) for 5 minutes. Membranes were then captured with a Chemi-doc XRS
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Imager (Quantity One V4.5.2 software, Bio-Rad) for 0-60 second exposure time. Band
densities were quantified using the densitometry analysis tool on the Quantity One program.
Filter Migration Assay: Chemotaxis was assessed using the ChemoTx 96-well cell
migration system, manufactured by Neuroprobe. Each well of the lower portion of the micro
plate apparatus was filled with 29 uL of the respective test solutions. The micro plate was
then covered with the ChemoTx® filter. The cells were washed once with PBS, centrifuged
at 1200 RPM and then the cells were re suspended in PBS to a concentration of 0-200,000
cells per 25 uL. Then 25 uL of the cell solution was placed on the filter pore for each
respective well. The plate was then covered and allowed to incubate at 37ºC for 0-6 hours.
The plate was removed and the top of the filter was rinsed with PBS. The filter was then
removed from the micro plate and the filter was allowed to dry. Then, ice cold 100%
methanol was used to rinse the lower portion of the filter plate for 20 seconds. The methanol
was poured off and then the filter was allowed to dry. A 6 mL mixture of 1 part ddH2O: 1
part Wright-Giemsa stain was then prepared. The stain mixture was added to the lower
portion of the filter plate. The plate was incubated at room temperature for 10-15 minutes,
shaking every 2 minutes. The stain was rinsed off and the entire plate was then submerged in
cool water twice using fresh water each wash. The filter plate was then allowed to dry. Each
well on the lower portion of the filter plate was counted under a microscope at 400x
magnification (average cell count of 3 non-overlapping fields of vision). The chemotactic
index (CI), the ratio of cells that transmigrated through the filter in the presence versus the
absence (=PBS/control) of the test solutions, was then calculated.
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Statistics:
Data are expressed as mean ± standard error of the mean (SEM) of n
independent experiments that were performed on different days. Differences between assays
were analyzed with repeated measures analysis of variance (ANOVA) with Dunnett's
multiple comparison tests as appropriate, to control for multiple testing. A two- tailed p <
0.05 was considered significant. Data were analyzed using the GraphPad-Prism 5 software.

CHAPTER FOUR
RESULTS
Specific Aim 1: To assess and compare the activation of important intracellular signal
transduction pathways upon CXCR4 activation with SDF-1! and ubiquitin.
To exclude that changes of the ubiquitin concentration in the THP-1 cell culture
supernatant would interfere with subsequent experiments, we measured cell viability, total
cell number, and the ubiquitin concentration in the culture supernatant when cells were
cultured in the presence and absence of serum for 0-72 hours. Fig. 4-1 (left panel) shows that
the cell viability remained above 95% and the cell number increased when cells were
cultured in the presence of serum. The cell viability decreased and the total cell number
remained constant when cells were cultured without serum (Fig. 4-1 right panel).

Figure 4-1. Cell number and percent cell viability of THP-1 cells during culture. THP-1
cells were cultured for various time points, Cell number (!) and percent viability (") (n=3).
Left: Cell number and percent cell viability when cells are cultured in the presence of serum.
Right: Cell number and percent cell viability when cells are cultured without serum.
25
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Fig. 4-2 shows that the ubiquitin concentration in RPMI media alone at the beginning
of cell culture was 15±3.0 ng/mL and 40±1.28 ng/mL after supplementation with serum.
There was not an observable change of the ubiquitin concentration in RPMI media during
cell culture with or without serum. These results suggest that for the chosen culture
conditions, changes in the ubiquitin concentration of the culture supernatant in the presence
or absence of serum will not interfere with subsequent experiments.

Figure 4-2. Ubiquitin concentrations in THP-1 cell culture supernatants supplemented
with or without serum. THP-1 cells were cultured for various time points and ubiquitin
concentrations in the supernatant were measured with an indirect competitive ubiquitin
ELISA (n=3). Left: Ubiquitin concentration of culture supernatant when cells are cultured in
the presence of serum. Right: Ubiquitin concentration of culture supernatant when cells are
cultured in the absence of serum.
Aim 1A. To screen the phosphorylation status of multiple MAPKs after CXCR4
activation with ubiquitin and SDF-1! utilizing a human phospho-MAPK array
To screen the phosphorylation status of multiple protein kinases after stimulating
cells with ubiquitin and SDF-1!, THP-1 cells were incubated with 0 or 1 µM of ubiquitin or
SDF-1! for 10 minutes at 37°C. Whole cell lysates were then probed for protein kinase
phosphorylation utilizing a human phospho MAPK array. Fig. 4-3 shows representative
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images of the array membranes from experiments when cells were treated with vehicle
(control), ubiquitin, or SDF-1!. The numbers on the array membrane correspond to the spot
positions for phosphorylated ERK1 (1), ERK2 (2), RSK 1 (3), Akt 1 (4), Akt 2 (5) and Akt
pan (6). The chemiluminescence signal of each spot corresponds to the degree of
phosphorylation of each protein kinase. Although there was considerable variation among the
individual experiments for some of the protein kinases, cells stimulated with ubiquitin and/or
SDF-1! consistently showed an increase in the densities of the spots that correspond to
phosphorylated ERK1/2, RSK1, and Akt, as compared with untreated cells.

Figure 4-3. Protein kinase phosphorylation after stimulation of THP-1 cells with
ubiquitin and SDF-1!. A human phospho MAPK array was used to screen the
phosphorylation status of multiple MAPKs. Typical images of the proteome array
membranes after vehicle (control), ubiquitin, and SDF-1! treatment. The numbers on the
array membrane correspond to the spot positions for phosphorylated ERK1 (1), ERK2 (2),
RSK 1 (3), Akt 1 (4), Akt 2 (5) and Akt pan (6).
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Fig. 4-4 shows the densitometric quantification of the spot densities that correspond to each
phosphorylated protein kinase after treatment of THP-1 cells with ubiquitin and SDF-1!
from 4 independent experiments; the spot densities are given as normalized pixel densities
(1=control, dashed line). The floating bars (white: SDF-1! treatment; grey: ubiquitin
treatment) extend from the minimum to the maximum and the horizontal line shows the
mean. The chemiluminescence signals that correspond to ERK1/2, RSK1, and Akt, suggest
that stimulation of THP-1 cells with ubiquitin and SDF-1! result in phosphorylation of the
MAPKs, as compared to the unstimulated cells.

Figure 4-4. Protein kinase phosphorylation after stimulation of THP-1 cells with
ubiquitin and SDF-1!. A human phospho MAPK array was used to screen the
phosphorylation status of multiple MAPKs. Densitometric quantification of spot densities, as
in Fig. 4-3 (n=4). Spot densities are given as normalized pixel densities (1= unstimulated
cells, dashed line). The bars (white: SDF-1! treatment; grey: ubiquitin treatment) extend
from the minimum to the maximum; the horizontal line shows the mean.
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Aim 1B. To confirm positive signals from the MAPK array by Western blotting
To confirm the results from the proteome array that ERK1/2, Akt, and RSK1 are
phosphorylated after THP-1 cells are stimulated with ubiquitin and SDF-1!, we treated THP1 cells with 1 µM ubiquitin or SDF-1! for 10 minutes and performed Western blot
experiments. Fig. 4-5 shows representative images from Western blots performed with
antibodies directed against phosphoERK1/2, phosphoAkt, and phosphoRSK1. The bands
correspond to a phosphorylated serine/threonine protein kinase. Upon stimulation with
ubiquitin or SDF-1!, there was an increase in the band density of phosphoERK1/2,
phosphoAkt, and phosphoRSK1 as compared to cells that were not treated. Pretreatment of
the THP-1 cells with the selective CXCR4 antagonist AMD3100 prevented the observed
increase of the band densities that correspond to phosphoERK1/2, phosphoAkt, and
phosphoRSK1 after cell stimulation with ubiquitin and SDF-1!. These results confirm that
ERK1/2, Akt, and RSK1 are phosphorylated after THP-1 cells are stimulated with ubiquitin
or SDF-1! and suggest that these effects are mediated through CXCR4.
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Figure 4-5. CXCR4 induced protein kinase phosphorylation. Western blot analyses of
MAPK phosphorylation after stimulation of THP-1 cells with ubiquitin and SDF-1!. Top
(phosphoERK 1/2), Center (phosphoRSK1), Bottom (phosphoAkt). Cells were pre-treated
with or without AMD3100 and stimulated with 1 µM of ubiquitin or SDF-1! for 10 minutes
at 37°C, as indicated.
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Aim 1C. To define and compare the time course of phosphorylation of the identified
serine/threonine protein kinases after CXCR4 activation with SDF-1! and ubiquitin
To define the time course of the respective serine/threonine protein kinase
phosphorylation, we stimulated THP-1 cells with 1µM of ubiquitin or SDF-1! for 0, 5, 10,
15, or 30 minutes and performed Western blot experiments with antibodies directed against
phosphoERK1/2, phosphoAkt, and phosphoRSK1. The left panels of Fig. 4-6 show
representative images from the Western blots. Upon stimulation with ubiquitin or SDF-1!,
there were time dependent increases in the band densities corresponding to phospoERK1/2,
phosphoAkt, and phosphoRSK1, as compared to untreated control. The right panels of Fig.
4-6 show the densitometric quantifications of chemiluminescence signals of the bands after
cell stimulation with ubiquitin or SDF-1! from 5-10 independent experiments.
Measurements of the time progression of the phosphorylation status of these protein kinases
confirm that cell activation with both ligands result in a comparable increase in protein
kinase phosphorylation. With ubiquitin activation, the increase of phosphorylation occurred
transiently and declined within 30 minutes. In contrast, the increase of phosphorylation was
sustained for 30 minutes with SDF-1! activation.
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Figure 4-6. Time course of CXCR4 induced protein kinase phosphorylation. Western
blot analyses of MAPK phosphorylation after stimulation of THP-1 cells with ubiquitin and
SDF-1!. Left panel: Top (pERK1/2), Center (pRSK1), Bottom (pAkt), after stimulation of
cells with 1 µM of ubiquitin or SDF-1! for 0-30 minutes. Right panel: Quantification of the
chemiluminescence signals after stimulation as on the left. White Bars: SDF-1! stimulation.
Grey Bars: Ubiquitin stimulation. N=5-10. *: p<0.05 vs. unstimulated cells.
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Specific Aim 2: To determine and compare the effects of ubiquitin and SDF-1! on
chemotaxis.
Aim 2A. To establish and optimize a chemotaxis assay
The regulation of cell trafficking is considered as a key function of the SDF1!/CXCR4 axis. Whether ubiquitin also has chemotactic activity, however, is unknown.
Therefore, we used the chemotactic response of THP-1 cells as a functional read-out for
CXCR4 agonist activity of ubiquitin and SDF-1!. Fig. 4-7 shows the average chemotactic
indices (CI) from 7 independent filter migration experiments in which the concentration
dependency of the chemotactic activity of ubiquitin and SDF-1! were tested. When
compared with SDF-1!, cell migration towards ubiquitin was detectable at similar
concentrations. However, the CI at concentrations that induced maximal cell migration was
lower with ubiquitin (CI: 4.2±0.9 with ubiquitin vs. 7.1±1.4 with SDF-1!; p<0.05) (Fig. 4-7).

Figure 4-7. SDF-1!/Ubiquitin induced chemotaxis. Dose dependent migration of THP-1
cells toward a ubiquitin (#) and SDF-1! (!) gradient (n=7). *: p<0.05 vs. cells in the
presence of PBS in lower compartment.
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To provide additional evidence for chemotactic activity, we used ubiquitin, SDF-1!,
and/or AMD3100 to disrupt the concentration gradients. Fig. 4-8 shows the migration of
THP-1 cells in the presence or absence of ubiquitin, SDF-1! or AMD3100 (AMD, 10 µM) in
the upper (top) and lower (bottom) compartment as indicated in the graph (n=4). Ubiquitin
and SDF-1! were used at concentrations (2 experiments with 1 nM, 2 experiments with 10
nM) that showed maximal chemotactic activity, as determined in Fig. 4-7. Induction of cell
migration by ubiquitin and SDF-1! required a concentration gradient; AMD3100 also
prevented cell migration. A SDF-1! concentration gradient induced a chemotactic response
in the presence of ubiquitin, whereas ubiquitin concentration gradients did not produce
chemotactic movements in the presence of SDF- 1!. This is consistent with the weaker
chemotactic activity of ubiquitin that we determined in the dose response experiments from
Fig. 4-7. These results suggest that both molecules possess chemotactic activity, which is
mediated through CXCR4.
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Figure 4-8. CXCR4 mediated chemotaxis. Migration of THP-1 cells in the presence or
absence of ubiquitin, SDF-1! or AMD3100 (AMD, 10 µM) in the upper (top) and lower
(bottom) compartment, as indicated in the graph (n=4). Ubiquitin and SDF-1! were used at
concentrations (2 experiments with 1 nM, 2 experiments with 10 nM) that showed maximal
chemotactic activity, as determined in Fig. 4-7. *: p<0.05 vs. cells in the upper compartment
and of ubiquitin in the lower compartment. #: p<0.05 vs. cells in the presence of PBS in the
upper compartment and of ubiquitin in the lower compartment. ‡: p<0.05 vs. cells in the
presence of PBS in the upper compartment and of SDF-1! in the lower compartment.
There was considerable variability among the previous chemotaxis assays. Therefore,
we sought to optimize the assay. To determine if the 8-micron filter pore size is appropriate
for filter migration assays with THP-1 cells, we performed experiments in parallel with filter
plates with an 8 or 5-micron pore size, respectively. Fig. 4-9 shows the average CIs from 3
filter migration experiments performed in parallel on plates with 8-micron and with 5-micron
pore sizes. Many of the CIs were higher on the 8-micron pore size plate compared to the 5-
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micron pore size plate. Therefore, this suggests that filter plates with 5-micron pore size limit
chemotactic movement of THP-1 cells. Thus, plates with 8-micron pore size were used in
subsequent experiments.

Figure 4-9. Filter migration assay-filter plate pore size optimization. CIs from parallel
filter migration assays performed with THP-1 cells on a 5 µm and 8 µm pore size plates
(n=3). Cell migration of THP-1 cells we assessed toward a ubiquitin gradient (0.001-1000
nM).
We next evaluated the amount of time the THP-1 cells were allowed to incubate at
37°C and performed filter migration assays at various incubation times. Fig. 4-10 shows the
average CIs from 3 independent experiments when cells were incubated for 0, 2, 3, 4, or 6
hours. The highest CI for ubiquitin, top, and SDF-1!, bottom, was observed after three
hours. CI decreased when cells were allowed to incubate for more than 3 hours and decreased
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near control CI values by 6 hours. This suggests that the optimal time to incubate the cells for
filter migration assays is 3 hours.

Figure 4-10. Filter migration assay-cell incubation time optimization. Filter migration
assays were performed with THP-1 cells and were allowed to incubate for 0-6 hours (n=3).
Top: Ubiquitin and Bottom: SDF-1!, were used at a concentration (10 nM) that showed
maximal chemotactic activity, as determined in Fig. 4-7.
Lastly, we optimized the cell number used for each well on the chemotaxis filter
plate. Fig. 4-11 shows the average CIs from 6 independent filter migration experiments using
an 8-micron pore size plate and 3 hour incubation time at 37°C with either 5 x 104, 10 x 104,
or 20 x 104 cells per well. Ubiquitin and SDF-1! were used at a concentration (10 nM) that
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showed maximal chemotactic activity, as determined in Fig. 4-7. The highest CI for ubiquitin
and SDF-1! was observed using 20 x 104 cells per well.

Figure 4-11. Filter migration assay-cell number optimization. Cell migration assays using
5 x 104, 10 x 104, and 20 x 104 THP-1 cells per well towards (Left): ubiquitin and (Right):
SDF-1! (n=6). Ubiquitin and SDF-1! were used at a concentration (10 nM) that showed
maximal chemotactic activity, as determined in Fig. 4-7.
Aim 2B. To determine and compare chemotactic effects of ubiquitin and SDF-1! under
optimized conditions
To compare the chemotactic effects of ubiquitin and SDF-1!, we repeated the filter
migration experiments under optimized conditions. Fig. 4-12 shows the average CIs from 6
independent cell migration experiments. THP-1 cells migrated dose dependently towards
ubiquitin and SDF-1!, as was described before (Fig. 4-7). Under optimized conditions,
ubiquitin is 4-5 times less efficacious than SDF-1! in promoting chemotaxis because the CI
at concentrations that induced maximal cell migration was lower with ubiquitin (CI: 5.99±1.1
with ubiquitin vs. 19.89±3.28 with SDF-1!). SDF-1! and ubiquitin are of similarly potency
because the concentrations that induced cell migration are similar for both ligands.
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Figure 4-12. Filter migration assays performed under optimized conditions. Filter
migration assays using 20 x 104 THP-1 cells toward a ubiquitin (!) and SDF-1! (!)
gradient (n=6).
It is known that SDF-1! directs migration of freshly isolated leukocytes, but it is
unknown whether ubiquitin also induces migration. Therefore, to assess whether ubiquitin
also directs cell migration of leukocytes, we isolated PBMCs from human venous blood and
performed filter migration assays. We first performed experiments with 8 and 5-micron pore
size filter plates, respectively, to assess whether the 8-micron filter pore size is appropriate
for PBMCs. Fig. 4-13 shows the average CIs from 3 chemotaxis experiments performed in
parallel on plates with a 5-micron pore size and on plates with 8-micron pore size. The
correlation of the CIs from experiments done in parallel on plates with a 5 and 8-micron filter
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pore size is linear. Therefore, either the 8 or 5-micron filter pore size plates are suitable and
we used 8-micron filter pore size plates for experiments with PBMCs.

Figure 4-13. Filter plate pore size optimization of migration assays with freshly isolated
leukocytes. CIs from experiments using PBMCs performed in parallel on plates with 5 and
8-micron pore size (n=3). Cell migration of PBMCs toward a ubiquitin gradient (0.001-1000
nM) (r2=0.1499).
Fig. 4-14 shows the average CIs from 5 independent filter migration experiments
using an 8-micron filter pore size plate under conditions described for THP-1 cells. PBMCs
migrated dose dependently towards ubiquitin and SDF-1!. Compared with SDF-1!, cell
migration towards ubiquitin was detectable at similar concentrations. However, the CI at
concentrations that induced maximal cell migration was lower with ubiquitin (5±0.48)
compared to SDF-1! (27±3.3). Similar to THP-1 cells (Fig. 4-12), ubiquitin is 4-5 times less
efficacious than SDF-1! in promoting chemotaxis, but of similar potency.
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Figure 4-14. Filter migration assays with PBMCs. Dose dependent migration of PBMCs
toward a ubiquitin (#) and SDF-1! (!) gradient (0.001-1000 nM) (n=5).
Aim 2C. To characterize the signaling events leading to chemotaxis induced by
ubiquitin and SDF-1!
The intracellular signals responsible for chemotaxis in response to SDF-1! have been
previously characterized (69,70,72,82,83); whether these signals are responsible for
chemotaxis in response to ubiquitin is unknown. Therefore, to characterize the intracellular
signals that are responsible for chemotaxis after cells are stimulated with ubiquitin, we
disrupted cognate CXCR4 signaling pathways with a variety of well-described
pharmacological agents. Fig. 4-15 shows the CIs of THP-1 cells that were incubated with a
pharmacological inhibitor, as compared to untreated control cells, from eight independent
experiments. The bars on the graphs (left: ubiquitin treatment; right: SDF-1! treatment)
correspond to the pharmacological agent used to disrupt the intracellular signals responsible
for chemotaxis. AMD3100, Pertussis Toxin, U73122, U73343 LY294002 and U0126
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significantly decreased chemotaxis of THP-1 cells for both ubiquitin and SDF-1!, as
compared to control. Further, TSA (used as a non-specific control) did not significantly
decrease the CIs of THP-1 cells for both ligands.

Figure 4-15. Intracellular signals responsible for CXCR4 mediated chemotaxis, THP-1
cells. Pharmacological agents as previously described were used to treat THP-1 cells and
characterize the signaling pathways responsible for chemotaxis after ubiquitin and SDF-1!
stimulation. The amount of chemotaxis compared to untreated cells (white) was measured.
Ubiquitin (Left) and SDF-1! (Right) were used at a concentration (10 nM) that showed
maximal chemotactic activity, as determined in Fig. 4-7 (n=8) *: p<0.05 vs. untreated control
cells.
Next, we evaluated the effects of the pharmacological inhibitors on freshly isolated
leukocytes to assess whether the intracellular signals that are responsible for cell migration in
THP-1 cells are similar for PBMCs. Fig. 4-16 shows the CIs of PBMCs that were incubated
with a pharmacological inhibitor compared to untreated control cells from six independent
experiments. The bars on each graph (left: ubiquitin treatment; right: SDF-1! treatment)
correspond to the pharmacological agent used to disrupt the intracellular signals responsible
for chemotaxis in PBMCs. Similar to Fig. 4-15, AMD3100, Pertussis Toxin, U73122,

43
U73343, LY294002 and U0126 also significantly decreased the CIs of PBMCs for both
ubiquitin and SDF-1!, as compared to control.

Figure 4-16. Intracellular signals responsible for CXCR4 mediated chemotaxis,
PBMCs. Pharmacological agents as previously described were used to treat PBMCs and
characterize the signaling pathways responsible for chemotaxis after ubiquitin and SDF-1!.
The amount of chemotaxis compared to untreated cells was measured. Ubiquitin (Left) and
SDF-1! (Right) were used at a concentration (10 nM) that showed maximal chemotactic
activity, as determined in Fig. 4-7. (n=6) *: p<0.05 vs. untreated control cells.

CHAPTER FIVE
DISCUSSION
Ubiquitin was recently characterized as a CXCR4 agonist but the intracellular
responses after CXCR4 activation with ubiquitin are largely unknown. In this study, we
investigated whether the distinct ligand binding sites for ubiquitin and SDF-1! on CXCR4
resulted in differential biological responses. Our results suggest that activation of CXCR4
with ubiquitin and SDF-1! result in similar intracellular signaling events and functional
consequences. Ubiquitin appears to be a weaker CXCR4 agonist than SDF-1!, however, and
this may correspond to differential CXCR4 signaling mediated via distinct ligand binding
sites on the receptor.
Our initial result provided evidence that we maintained healthy cells under our culture
conditions, and that the ubiquitin concentration in the culture supernatant would not interfere
with experiments to test our hypothesis. Our first finding that CXCR4 activation with
ubiquitin appears to result in similar intracellular signaling properties compared to SDF-1! is
supported by the MAPK array and subsequent Western blot experiments. Side-by-side
comparisons of MAPK phosphorylations after ubiquitin and SDF-1! stimulation of THP-1
cells showed that both ligands produced similar patterns in the membrane array. We then
used Western blot experiments and confirmed that ERK-1/2, RSK-1 and Akt are
phosphorylated in response to CXCR4 activation after cell stimulation with ubiquitin and
SDF-1! (53,120). Thus, the original thought was that the similar pattern of MAPK
44
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phosphorylation, after CXCR4 activation with both ligands, argues against differential
intracellular signaling properties (121). However, the time course Western blot experiments
provided evidence that there are differential signaling properties; MAPK phosphorylation
after CXCR4 activation with ubiquitin occurred more transiently compared to SDF-1!. It
might be speculated that the transient effects of MAPK phosphorlyation after cells were
incubated with ubiquitin may be due to increased activity of phosphatases specific for
ERK1/2, RSK-1, and Akt. However, it is unknown whether CXCR4 activation with ubiquitin
or SDF-1! results in phosphatase over expression and/or activation.
Our finding that CXCR4 activation with ubiquitin appears to result in a similar
functional response compared to SDF-1! is supported by our filter migration experiments.
We used THP-1 cells and freshly isolated leukocytes and found that SDF-1! and ubiquitin
displayed chemotactic activity at concentrations between 0.1 – 10 nM. This is in agreement
with the wide range of SDF-1! concentrations that have been previously reported to induce
chemotactic movements (130,131). Thus, it is reasonable to speculate that ubiquitin and
SDF-1! induced maximal receptor activation at these optimized concentrations. These
results also correspond to previous observations that intramuscular injection of ubiquitin led
to the accumulation of large numbers of lymphocytes in the CXC12 myoblast cell line (132),
which resembles the effects of SDF-1! after subcutaneous injection (122). Further, these
findings are concurrent with the affinity of SDF-1! for CXCR4 (Kd: 1.5 – 24 nM), which
has been reported with human peripheral blood monocytes, T-cells, and T-cell lines (32, 106,
107,133, 134). However, the range of concentrations observed that induced chemotactic
responses towards ubiquitin were 10-1000-fold below the affinity of ubiquitin for CXCR4
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(28). We can speculate that the lower chemotactic response is not due to the lower affinity of
ubiquitin for CXCR4, as compared to SDF-1!, because CXCR4 is fully activated with
ubiquitin under optimized conditions. Thus, It is possible that this phenomenon is a result of
the alternative ubiquitin-binding site on CXCR4 (43). These results suggest, however, that
only a small percentage of receptor occupancy by ubiquitin is necessary to elicit a cellular
response. Such a dose-response relationship has been described for other GPCRs, showing
half-maximal and maximal responses at receptor occupancies of 0.13% and of 0.8% (135,
136), respectively. We also optimized the filter migration assay (filter pore size, time cells
were allowed to incubate, and cell number used per well) and confirmed and extended
previously described results under optimized conditions (26, 122).
Our findings from filter migration experiments after we disrupted cognate CXCR4
signaling pathways show that CXCR4 activation with ubiquitin and SDF-1! result in similar
intracellular signaling properties. The finding that THP-1 cells and PBMCs migrated toward
ubiquitin or SDF-1!, that both ligands function through CXCR4 (133,138), and cells rely on
a similar pattern of intracellular signaling including G!i (32), PLC (138), PI3 kinase (139)
and ERK1/2 (137,140) to induce chemotaxis is in agreement with previous literature. It must
be noted that pre-treatment of cells with U73122 had the strongest effects in both cell types
and this may explain why there was a significant reduction in chemotaxis when cells were
pre-treated with U73343.
Several studies show that CXCR4-"-arrestin signaling leads to phosphorylation of
ERK1/2 and Akt, and may results in prolonged signal transduction events (123-125). There
are also studies that show "-arrestin mediated signaling leads to prolonged ERK1/2 signaling
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and actin filament assembly at the leading edge of cells that is critical for GPCR mediated
chemotactic responses (126-129). Thus, the transient MAPK phosphorylation after cell
stimulation with ubiquitin and the lower efficacy of ubiquitin to induce a chemotactic
response in THP-1 cells and PBMCs could suggest there is insufficient "-arrestin recruitment
to CXCR4 after ubiquitin stimulation.
One limitation of our study is that our filter migration assays have thus far been
conducted in vitro using THP-1 cells and PBMCs. There is evidence that multiple cancer cell
types metastasize to SDF-1! (116, 117), and ubiquitin may have important therapeutic
potential for cancer treatment. In order to confirm the results from our experiments, in vivo
experiments are required. Another limitation is that, although Western blot experiments
showed MAPK phosphorylation after cell stimulation with ubiquitin and SDF-1!, this was
not indicative of the activity of the MAPKs and may not influence cellular function.
Additionally, using PBMCs was a limitation for this study because PBMCs are not a
homogenous cell population. The last limitation of note was while the pharmacological
inhibitors used in the experiments have been well described, we would need to perform
additional experiments to confirm that the intracellular signals are inactive.
Working model for CXCR4 activation with ubiquitin and SDF-1!
The results from the current study show that ubiquitin induces serine/threonine
protein kinase activation in THP-1 cells and this appears to be specific through CXCR4.
However, the response was more transient compared to SDF-1! induced CXCR4 activation.
Additionally, the results demonstrate ubiquitin induces a chemotactic response specific
through CXCR4 with THP-1 cells and PBMCs, but the response was less compared to SDF-
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1!. However, the signaling events we tested that are involved in a chemotactic response were
similar for ubiquitin and SDF-1!. In summary, the transient serine/threonine protein kinase
activation and differences in chemotaxis may be explained by the amount of "-arrestin
recruitment to the activated receptor. A working model is presented in Figure 5-1.
Future directions for the investigation of functional selectivity through CXCR4
activation with ubiquitin and SDF-1!
It has been described that "-arrestin is a crucial intracellular signal transducer and
leads to functional responses. Therefore, a future study could investigate the magnitude of "arrestin recruitment to CXCR4 upon stimulation with ubiquitin and SDF-1!. Additionally,
GRKs phosphorylate CXCR4 at the third intracellular loop and this results in the active
recruitment and increased affinity of "-arrestin to the receptor. Therefore a study of the
interaction of GRKs with CXCR4 after activation with ubiquitin and SDF-1!, the
phosphorylation status of the third intracellular loop of CXCR4, and finally the magnitude of
"-arrestin recruitment to CXCR4 would provide additional evidence of differential receptor
signaling.
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Figure 5-1. Working hypothesis for differential signaling through CXCR4 activation
with ubiquitin and SDF-1!. Our data demonstrate that ubiquitin induces serine/threonine
protein kinase activation in THP-1 cells and this is specific through CXCR4. Our data also
showed ubiquitin induces a chemotactic response specific through CXCR4 mediated
intracellular signals. The serine/threonine kinase signals were more transient and chemotaxis
was less with ubiquitin compared to SDF-1!. It is possible ubiquitin is a biased agonist and
there is minimal or even no "-arrestin signaling with ubiquitin induced CXCR4 activation.
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